Accéder au contenu
Merck

Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction network.

PloS one (2013-06-14)
Bi-Qing Li, Bing Niu, Lei Chen, Ze-Jun Wei, Tao Huang, Min Jiang, Jing Lu, Ming-Yue Zheng, Xiang-Yin Kong, Yu-Dong Cai
RÉSUMÉ

Acquired immune deficiency syndrome (AIDS) is a severe infectious disease that causes a large number of deaths every year. Traditional anti-AIDS drugs directly targeting the HIV-1 encoded enzymes including reverse transcriptase (RT), protease (PR) and integrase (IN) usually suffer from drug resistance after a period of treatment and serious side effects. In recent years, the emergence of numerous useful information of protein-protein interactions (PPI) in the HIV life cycle and related inhibitors makes PPI a new way for antiviral drug intervention. In this study, we identified 26 core human proteins involved in PPI between HIV-1 and host, that have great potential for HIV therapy. In addition, 280 chemicals that interact with three HIV drugs targeting human proteins can also interact with these 26 core proteins. All these indicate that our method as presented in this paper is quite promising. The method may become a useful tool, or at least plays a complementary role to the existing method, for identifying novel anti-HIV drugs.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
1-Deoxynojirimycin, analytical standard